222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

15 trials found

diseases per page:

Showing 1 to 10 of 15 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-003767-25-DE (EUCTR)	08/03/2022	04/10/2021	A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplanadministered subcutaneously in P ...	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) ...	Trade Name: Aspaveli Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;United Kingdom;Switzerland;Italy;France;C ...
2	EUCTR2020-003767-25-ES (EUCTR)	25/02/2022	25/02/2022	A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplanadministered subcutaneously in P ...	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcet ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;United Kingdom;Switzerland;Italy;France;C ...
3	EUCTR2020-003767-25-NL (EUCTR)	16/02/2022	13/10/2021	A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplanadministered subcutaneously in P ...	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcet ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;United Kingdom;Switzerland;Italy;France;C ...
4	EUCTR2020-003767-25-PL (EUCTR)	08/02/2022	09/11/2021	A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplanadministered subcutaneously in P ...	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) ...	Trade Name: Aspaveli Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;United Kingdom;Italy;Switzerland;France;C ...
5	NCT05067127 (ClinicalTrials.gov)	November 12, 2021	23/9/2021	Phase III Study Assessing the Efficacy and Safety of Pegcetacoplanin Patients With C3 Glomerulopathy ...	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ...	C3G;IC-MPGN;C3 Glomerulopathy;C3 Glomerulonephritis;Complement 3 Glomerulopathy;Complement 3 Glomeru ...	Drug: Pegcetacoplan;Other: Placebo	Apellis Pharmaceuticals, Inc.	NULL	Recruiting	12 Years	N/A	All	90	Phase 3	Spain;Switzerland;United States;Australia;Belgium;France;Italy;Netherlands;Poland
6	EUCTR2020-002637-15-FR (EUCTR)	09/06/2021	02/02/2021	Phase 2, multicenter, open-label, randomized, controlled study is designed to evaluate the safety an ...	AN OPEN-LABEL, RANDOMIZED, CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGCETAC ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN); ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	United States;France;Argentina;Spain;Brazil;Austria;Australia;Netherlands;United Kingdom;Switzerland ...
7	EUCTR2020-002637-15-IT (EUCTR)	09/04/2021	04/06/2021	Phase 2, multicenter, open-label, randomized, controlled study is designed to evaluate the safety an ...	An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetac ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) ...	Product Name: Pegcetacoplan Product Code: [APL-2] INN or Proposed INN: Pegcetacoplan Trade Name: Preven ...	APELLIS PHARMACEUTCIALS, INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	France;Argentina;Spain;Brazil;Austria;Australia;Netherlands;United Kingdom;Switzerland;Italy;United ...
8	EUCTR2020-002637-15-AT (EUCTR)	01/04/2021	23/12/2020	Phase 2, multicenter, open-label, randomized, controlled study is designed to evaluate the safety an ...	AN OPEN-LABEL, RANDOMIZED, CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGCETAC ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN); ...	Trade Name: Aspaveli Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	France;United States;Argentina;Spain;Brazil;Australia;Austria;Netherlands;United Kingdom;Italy;Switz ...
9	EUCTR2020-002637-15-NL (EUCTR)	29/03/2021	04/01/2021	Phase 2, multicenter, open-label, randomized, controlled study is designed to evaluate the safety an ...	An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetac ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN); ...	Trade Name: Aspaveli Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	France;United States;Argentina;Spain;Brazil;Austria;Australia;Netherlands;Italy;Switzerland;United K ...
10	NCT04572854 (ClinicalTrials.gov)	February 23, 2021	29/9/2020	Study Assessing the Safety and Efficacy of Pegcetacoplanin Post-Transplant Recurrence of C3G or IC-M ...	An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetac ...	C3G;IC-MPGN;Renal Transplant;Complement 3 Glomerulopathy;Complement 3 Glomerulopathy (C3G);Dense Dep ...	Drug: Pegcetacoplan	Apellis Pharmaceuticals, Inc.	NULL	Recruiting	18 Years	N/A	All	12	Phase 2	United States;Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United K ...

First Previous1 2Next Last